Sanofi (NASDAQ:SNY) Shares Purchased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. increased its stake in shares of Sanofi (NASDAQ:SNY) by 1.0% during the 4th quarter, Holdings Channel.com reports. The fund owned 126,811 shares of the company’s stock after purchasing an additional 1,216 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Sanofi were worth $6,116,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Abel Hall LLC increased its position in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after buying an additional 194 shares during the period. PDS Planning Inc boosted its holdings in shares of Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after acquiring an additional 200 shares during the period. Financial Advocates Investment Management grew its position in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after acquiring an additional 206 shares during the last quarter. Angeles Investment Advisors LLC increased its holdings in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after acquiring an additional 210 shares during the period. Finally, Keudell Morrison Wealth Management raised its position in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Trading Up 0.6 %

Shares of SNY stock opened at $54.47 on Friday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a market capitalization of $138.24 billion, a P/E ratio of 21.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $51.65 and its two-hundred day moving average is $52.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.